

Press Release

Media Contact

Martin Kunze
T +49 6172 609-2115
martin.kunze@fresenius.com

www.freseniusmedicalcare.com

November 7, 2019

Fresenius Medical Care Ventures leads \$100 million Series B financing for eGenesis

Fresenius Medical Care, the world's leading provider of dialysis services and products, has led the \$100 million Series B equity financing for eGenesis through its corporate venture capital arm Fresenius Medical Care Ventures GmbH. eGenesis is a leading player in the field of xenotransplantation of kidneys for patients with advanced renal disease. Founded by Luhan Yang and George Church in 2016, eGenesis is using gene editing technology to enable the transplantation of pig kidneys into humans safely and without an immune response rejecting the organ.

Dr. Olaf Schermeier, Fresenius Medical Care's CEO for Global Research and Development, said: "Our investment in eGenesis reflects our commitment to harnessing cutting edge technologies to bring the most advanced therapeutic options to our patients worldwide. Xenotransplantation could significantly improve the lives of patients with kidney failure, reduce overall costs and dramatically increase the number of kidneys available for transplant. Fresenius Medical Care has always been at the forefront of innovation in treating renal diseases and making xenotransplantation a reality will demonstrate the continuation of this leadership."

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,003 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 342,488 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit www.freseniusmedicalcare.com.

Fresenius Medical Care Ventures was established to invest in start-ups and early-stage companies in the healthcare sector. The investments are targeted to support Fresenius Medical Care's corporate strategy to grow continuously in our core business and to expand into new business areas. Fresenius Medical Care Ventures is complementing the corporate activities in external innovation.

For more information visit www.fmcv.com.

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need. eGenesis has a clear path forward to advance an initial product to the clinic for at-risk patients on the transplant waitlist, with the longer-term potential of addressing a broader population and expanding the applicability of transplantation into other arenas such as cell therapy. eGenesis is a regenerative medicine company with a focus on kidney & liver disorders, diabetes and oncology.

For more information visit www.egenesisbio.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.